GRAIL Sees Growth in Q4 2024, Secures Key Partnerships for Cancer Detection

2 min read | February 20, 2025 10:40 PM PST | By Team Kalkine Media

GRAIL Sees Growth in Q4 2024, Secures Key Partnerships for Cancer Detection — Image source: Shutterstock

Revenue and Financial Performance

GRAIL’s total revenue grew 26% year-over-year in Q4, reaching $38.3 million, driven by a 39% increase in Galleri test sales to $31.6 million. For the full year, revenue surged 35% to $125.6 million, with Galleri contributing $108.6 million (a 45% increase).

The company’s net loss for Q4 improved to $97.1 million, a 48% reduction from the previous year. However, the full-year net loss stood at $2.0 billion, impacted by a $1.4 billion goodwill impairment related to the Illumina acquisition.

GRAIL ended 2024 with a strong cash position of $766.8 million, ensuring resources for further expansion and innovation.

Expanding Access Through TRICARE Coverage

A major milestone in 2024 was TRICARE Health Insurance adding the Galleri test as a covered benefit for individuals aged 50 and older at elevated risk for cancer. This expands access to millions of U.S. military personnel, retirees, and their families.

Scientific Validation and Healthcare Integration

A Lancet Oncology study published in 2024 confirmed Galleri’s high patient satisfaction and minimal distress among those tested, reinforcing the test’s role in routine cancer screening.

In another breakthrough, GRAIL partnered with Quest Diagnostics, enabling doctors to order the Galleri test electronically via 7,400+ Quest locations. This integration simplifies test access, eliminating the need for patients to bring test kits to appointments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.